0001193125-26-041396 Sample Contracts

SHARE PURCHASE AGREEMENT AMONG ODYSSEY THERAPEUTICS, INC., RAHKO LIMITED, BALDERTON CAPITAL GENERAL PARTNER VI S.L.P AND ROBERT IAN HOROBIN AND MIRIAM CHA, AS SELLERS’ REPRESENTATIVES DATED AS OF OCTOBER 6, 2021
Share Purchase Agreement • February 6th, 2026 • Odyssey Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware

This Share Purchase Agreement (this “Agreement”), dated as of October 6, 2021, is made by and among ODYSSEY THERAPEUTICS, INC., a Delaware corporation (“Buyer”), RAHKO LIMITED, a private limited company incorporated in England & Wales (registered number 11609778) (the “Company”), BALDERTON CAPITAL VI S.L.P, acting by its general partner Balderton Capital General Partner VI S.à.r.l, of [***] (the “Seller”), and ROBERT IAN HOROBIN of [***] and MIRIAM CHA of [***], solely in their capacity as the Seller’s Representatives (as defined below).

View SourceView Similar (4)
MEMBERSHIP INTEREST PURCHASE AGREEMENT by and among ODYSSEY THERAPEUTICS, INC., IFM THERAPEUTICS, LLC, IFM MANAGEMENT, INC., IFM THERAPEUTICS GMBH IFM QUATTRO, INC., IFM CINQUE, INC., and IFM CONTINUA, INC. Dated as of May 6, 2022
Membership Interest Purchase Agreement • February 6th, 2026 • Odyssey Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware

This MEMBERSHIP INTEREST PURCHASE AGREEMENT (this “Agreement”), dated as of May 6, 2022, is entered into by and among Odyssey Therapeutics, Inc., a Delaware corporation (“Purchaser”), IFM Therapeutics, LLC, a Delaware limited liability company (“Parent”), IFM Management, Inc., a Delaware corporation (“Management”), IFM Therapeutics GmbH, a limited liability company under the laws of the Federal Republic of Germany (“IFM GmbH”), IFM Quattro, Inc., a Delaware corporation (“Quattro”), IFM Cinque, Inc., a Delaware corporation (“Cinque”) and IFM Continua, Inc., a Delaware corporation (“Continua” and, together with Quattro and Cinque, the “Sellers” and each a “Seller” ). Purchaser, Parent, Management, IFM GmbH and the Sellers are sometimes referred to individually as a “Party” and collectively as the “Parties.”

View SourceView Similar (2)
COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN TERRAY THERAPEUTICS, INC. AND ODYSSEY THERAPEUTICS, INC. Dated September 11, 2024
Collaboration and License Agreement • February 6th, 2026 • Odyssey Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

This COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into this 11th day of September, 2024 (the “Effective Date”), by and between Terray Therapeutics, Inc., a corporation organized under the laws of Delaware having its principal offices at 750 Royal Oaks Drive, Suite 100, Monrovia, CA 91016 (“Terray”), and Odyssey Therapeutics, Inc., a corporation organized under the laws of Delaware, having its principal offices at 51 Sleeper Street, Boston, MA 02210 (“Odyssey”). Terray and Odyssey are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

View Source